FDA Class II Recall Targets 3,744 Bottles of Generic Blood Pressure Meds for Dissolution Failures

Key points

• Macleods Pharmaceuticals recalled 3,528 bottles of 30-count and 216 bottles of 90-count tablets on October 7, 2026.
• The recall was triggered by failed dissolution specifications, meaning the pills may not release active ingredients at the proper rate.
• The FDA classified the recall as Class II on October 26, 2026, suggesting temporary or medically reversible adverse consequences.
• Affected lots include NDC 33342-246-07 and NDC 33342-246-10 with expiration dates of May 31, 2027.
• Brand-name Tribenzor is not part of the recall, but patients should verify if they are using the generic version.

Background

This recall follows a separate October 2026 recall of Viatris telmisartan tablets, highlighting ongoing scrutiny of blood pressure medication quality. Previous coverage noted that the FDA advises patients not to stop taking medication abruptly but to consult healthcare providers. The current recall involves a generic triple-combination medication, distinct from brand-name products, and focuses on dissolution testing failures that could render the drug ineffective.

Why it matters

The recall affects a common generic blood pressure medication, potentially impacting thousands of patients who rely on it for managing hypertension. Failed dissolution specifications could lead to ineffective treatment, posing risks to patients with high blood pressure. The Class II classification indicates that while the issue is unlikely to cause serious harm, it may result in temporary adverse effects, underscoring the importance of patient vigilance and consultation with healthcare providers.

What to watch

Patients are advised to check their medication lot numbers against the recalled lots and consult their healthcare providers before making any changes to their treatment. The FDA did not issue a news release for this recall, but letters were sent to notify businesses and individuals who may have the affected medications. Ongoing monitoring of drug safety and dissolution testing will likely continue to ensure patient safety.